CClinicalTrials.gg
CompletedNCT03182244Updated Sep 22, 2026Results posted

A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation

A Phase 3 interventional study of Gilteritinib and Cytarabine in AML With FLT3 Mutation, sponsored by Astellas Pharma Inc. Completed at 49 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by Astellas Pharma Inc · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
276
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study was to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated AML who were refractory to or had relapse after first-line AML therapy as shown with overall survival (OS) compared to salvage chemotherapy. In addition, this study evaluated safety as well as determined the overall efficacy in event-free survival (EFS) and complete remission (CR) rate of ASP2215 compared to salvage chemotherapy.

Read the detailed description

Participants considered an adult according to local regulations at the time of signing informed consent were randomized in a 1:1 ratio and received ASP2215 or salvage chemotherapy. Participants entered the screening period up to 14 days prior to the start of treatment. Prior to randomization, the investigator preselected a salvage chemotherapy regimen for each participant; options included low-dose cytarabine (LoDAC), mitoxantrone, etoposide and intermediate-dose cytarabine (MEC) or fludarabine, high-dose cytarabine and granulocyte colony-stimulating factor (FLAG). The randomization was stratified by response to first-line therapy and preselected salvage chemotherapy. Participants were administered treatment over continuous 28-day cycles.

Among the participants, approximately 20 Chinese participants who were randomized into the ASP2215 arm were allocated to the pharmacokinetic (PK) cohort. Participants in the PK cohort were requested to be hospitalized from the date of randomization (Day 1) to at least the completion of all the assessments planned on Day 2. All participants in the PK cohort underwent blood sampling for PK measurement of ASP2215. Participants in PK cohort were administered the study drug in the same manner and underwent the same efficacy and safety assessments as other participants except for blood sampling for additional PK measurements.

02

Conditions studied

  • AML With FLT3 Mutation

Keywords

  • gilteritinib
  • Acute Myeloid Leukemia (AML)
  • ASP2215
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Participant has a diagnosis of primary AML or AML secondary to myelodysplastic syndrome (MDS) according to World Health Organization (WHO) classification as determined by pathology review at the treating institution.
  • Participant is refractory to or relapsed after first-line AML therapy (with or without HSCT)

    • Refractory to first-line AML therapy is defined as:

      a. Participant did not achieve CR/CRi/CRp under initial therapy. A participant eligible for standard therapy must receive at least 1 cycle of an anthracycline containing induction block in standard dose for the selected induction regimen. A participant not eligible for standard therapy must have received at least 1 complete block of induction therapy seen as the optimum choice of therapy to induce remission for this participant.

    • Untreated first hematologic relapse is defined as:

      1. Participant must have achieved a CR/CRi/CRp with first-line treatment and has hematologic relapse.
  • Participant is positive for FLT3 mutation in bone marrow or whole blood as determined by the central lab. A participant with rapidly proliferative disease and unable to wait for the central lab results can be enrolled based on a local test performed after completion of the last interventional treatment. Participants can be enrolled from a local test result if the participants have any of the following FLT3 mutations: FLT3-internal tandem duplication (ITD), FLT3-tyrosine kinase domain (TKD)/D835 or FLT3-TKD/I836.
  • Participant has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
  • Participant is eligible for preselected salvage chemotherapy.
  • Participant must meet the following criteria as indicated on the clinical laboratory tests:

    • Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN)
    • Serum total bilirubin (TBL) ≤ 1.5 x ULN
    • Serum creatinine ≤ 1.5 x ULN or an estimated glomerular filtration rate of > 50 mL/min as calculated by the Modification of Diet in Renal Disease equation.
  • Participant is suitable for oral administration of study drug.
  • Participant agrees not to participate in another interventional study while on treatment.

Inclusion Criteria for COE:

Participant is eligible for the COE if they continue to meet all inclusion criteria from the main protocol in addition to the following when the participant is evaluated for eligibility to participate in the COE portion of the study:

  • Participant has received study treatment of either LoDAC, MEC or FLAG and has no response or progressive disease.
  • Participant have not received other antileukemic therapy after EOT (hydroxyurea is allowed for the control of peripheral leukemic blasts in participants with leukocytosis).
  • Participant agrees not to participate in another interventional study while on treatment.

Exclusion Criteria:

  • Participant was diagnosed as acute promyelocytic leukemia.
  • Participant has BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).
  • Participant has AML secondary to prior chemotherapy for other neoplasms (except for MDS).
  • Participant is in second or later hematologic relapse or has received salvage therapy for refractory disease.
  • Participant has clinically active central nervous system leukemia..
  • Participant has been diagnosed with another malignancy, unless disease-free for at least 5 years. Participants with treated nonmelanoma skin cancer, in situ carcinoma or cervical intraepithelial neoplasia, regardless of the disease-free duration, are eligible for this study if definitive treatment for the condition has been completed. Participants with organ-confined prostate cancer with no evidence of recurrent or progressive disease are eligible if hormonal therapy has been initiated or the malignancy has been surgically removed or treated with definitive radiotherapy.
  • Participant has received prior treatment with ASP2215 or other FLT3 inhibitors (with the exception of sorafenib and midostaurin used in first-line therapy regimen as part of induction, consolidation and/or maintenance).
  • Participant has clinically significant abnormality of coagulation profile, such as disseminated intravascular coagulation.
  • Participant has had major surgery within 4 weeks prior to the first study dose.
  • Participant has radiation therapy within 4 weeks prior to the first study dose.
  • Participant has congestive heart failure New York Heart Association (NYHA) class 3 or 4 or participant with a history of congestive heart failure NYHA class 3 or 4 in the past, unless a screening echocardiogram (ECHO) performed within 1 month prior to study entry results in a left ventricular ejection fraction (LVEF) that is ≥ 45%.
  • Participant with mean of triplicate Fridericia-corrected QT interval (QTcF) > 450 ms at Screening based on central reading.
  • Participant with Long QT Syndrome at Screening.
  • Participant with hypokalemia and hypomagnesemia at Screening (defined as values below lower limit of normal [LLN]).
  • Participant requires treatment with concomitant drugs that are strong inducers of CYP3A.
  • Participant requires treatment with concomitant drugs that are strong inhibitors or inducers of P-gp with the exception of drugs that are considered absolutely essential for the care of the participant.
  • Participant requires treatment with concomitant drugs that target serotonin 5-hydroxytryptamine receptor 1 (5HT1R) or 5-hydroxytryptamine receptor 2B (5HT2BR) receptors or sigma nonspecific receptor with the exception of drugs that are considered absolutely essential for the care of the participant.
  • Participant has an active uncontrolled infection.
  • Participant is known to have human immunodeficiency virus infection.
  • Participant has active hepatitis B or C or other active hepatic disorder.
  • Participant has any condition which makes the participant unsuitable for study participation.
  • Participant has active clinically significant (graft-versus-host disease) GVHD or is on treatment with systemic corticosteroids for GVHD.
  • Participant has an FLT3 mutation other than the following: FLT3-ITD, FLT3-TKD/D835 or FLT3-TKD/I836.

Exclusion Criteria for COE:

Participant will be excluded from participation in the COE if they meet any of the exclusion criteria listed in the main protocol or when the participant is evaluated for eligibility to participate in the COE portion of the study.

04

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
276 participants (actual)

Study arms

  • Experimental
    Gilteritinib

    Participants received 120 milligrams (mg) gilteritinib (3 tablets of 40 mg) orally, once a day in continuous 28-day cycles until treatment discontinuation criteria were met. Participants who met the treatment discontinuation criteria, entered the long-term follow-up period. Participants remained in the long-term follow-up period for up to 3 years from the participant's end of treatment visit or until discontinuation from the study.

    Drug: Gilteritinib

  • Active comparator
    Salvage chemotherapy

    Participants received salvage chemotherapy in continuous 28-day cycles per institutional guidelines:LoDAC:20mg cytarabine twice daily SC/IV for 10 days. MEC:mitoxantrone 6 milligrams per square meter(mg/m\^2)/day IV for 5 days (days 1 to 5), etoposide 100mg/m\^2/day IV for 5 days (days 1 to 5), cytarabine 1000mg/m\^2/day IV for 5 days (days 1 to 5). FLAG: granulocyte colony-stimulating factor (G-CSF) 300 micrograms per square meter (μg/m\^2) per day SC/IV for 5 days (days 1 to 5), fludarabine 30mg/m\^2/day IV for 5 days (days 2 to 6), cytarabine 2000mg/m\^2/day IV for 5 days (days 2 to 6). Participants meeting treatment discontinuation criteria, entered long-term follow-up, for up to 3 years from end of treatment visit/until study discontinuation. Based on interim analysis outcome, at investigators discretion, treatment period participants had option to enter crossover extension to receive 120mg gilteritinib, orally, once daily in continuous 28-day cycles until treatment discontinuation.

    Drug: Cytarabine · Drug: Mitoxantrone · Drug: Etoposide · Drug: G-CSF · Drug: Fludarabine

Interventions

  • DrugGilteritinib

    Tablet administered orally once daily.

    Also known as: ASP2215

  • DrugCytarabine

    Once/twice daily Intravenously (IV)/subcutaneously (SC).

  • DrugMitoxantrone

    Once daily IV injection.

  • DrugEtoposide

    Once daily IV injection.

  • DrugG-CSF

    Once daily IV/SC injection.

  • DrugFludarabine

    Once daily IV injection.

05

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from the date of randomization to the date of death due to any cause. Participants who were still alive or lost to follow up were censored at the time they were last known to be alive. Kaplan-Meier (KM) estimates was used for analysis.

    Time frame: From the date of randomization up to the date of death (up to approximatley 74 months)

Secondary outcomes

  1. Event-Free Survival (EFS)

    EFS: time from the date of randomization until the date of documented relapse, treatment failure, death, reported off treatment relapse or new AML therapy start whichever occued first, including the long-term follow-up data. KM estimate was used for analysis. Relapse was defined as documentation of any of following events: * Bone marrow (BM) blasts ≥ 5% (not attributable to regenerating BM) * Reappearance or new appearance of extramedullary leukemia * Reappearance of significant numbers of peripheral blasts Treatment failure: Treatment failure was defined as participant who ends treatment without having a previous response of CR, CR with incomplete platelet recovery (CRp) and CR with incomplete hematological recover (CRi).

    Time frame: From the date of randomization up to the date of documented relapse, treatment failure or death from any cause, off-treatment relapse and start of new AML therapy (up to approximately 74 months)

  2. Complete Remission (CR) Rate

    Percentage of participants with CR were reported. CR: morphologically leukemia-free state, with absolute neutrophil count (ANC) \> 1x10\^9 per liter (1x10\^9/L), platelet count ≥ 100x10\^9/L and normal marrow differential with \<5% blasts. They were red blood cell (RBC) and platelet transfusion independent and no evidence of extramedullary leukemia or Auer rods was necessary.

    Time frame: From the date of randomization up to approximately 74 months

  3. Duration of CR

    Duration of CR: time from the date of achieving first CR until date of first documented relapse for participants who achieved CR. KM estimate was used for analysis. CR: morphologically leukemia-free state, with ANC\> 1x10\^9/L, platelet count ≥ 100x10\^9/L and normal marrow differential with \< 5% blasts. They were RBC and platelet transfusion independent and no evidence of extramedullary leukemia. Relapse was defined as documentation of any of following events: * BM blasts ≥ 5% (not attributable to regenerating BM) * Reappearance or new appearance of extramedullary leukemia * Reappearance of significant numbers of peripheral blasts

    Time frame: From date of achieving CR until date of confirmed relapse (maximum duration was 53.4 months )

  4. Duration of Composite Complete Remission (CRc)

    Duration of CRc: time from date of achieving first CRc until date of first documented relapse for participants who achieved CRc. KM estimate was used for analysis. CRc: rate of all complete \& incomplete remissions \[CR + CRp + CRi\]. CR: morphologically leukemia-free state, with ANC\> 1x10\^9/L, platelet count ≥ 100x10\^9/L and normal marrow differential with \<5% blasts. They were RBC and platelet transfusion independent and no evidence of extramedullary leukemia. CRp: met all CR criteria except incomplete platelet recovery (\< 100x10\^9/L). CRi: met all CR criteria, except for incomplete hematological recovery with residual neutropenia \< 1x10\^9/L with or without complete platelet recovery. Relapse: BM blasts ≥ 5%, reappearance or new appearance of extramedullary leukemia, reappearance of significant numbers of peripheral blasts.

    Time frame: From date of achieving CRc until date of confirmed relapse (maximum duration was 60 months)

  5. Duration of CR/Complete Remission With Partial Hematologic Recovery (CRh)

    Duration of CR/CRh: time from date of achieving first CR/CRh until date of first documented relapse for participants who achieved CR/CRh. KM estimate was used for analysis. CR: morphologically leukemia-free state, with ANC\> 1x10\^9/L, platelet count ≥ 100x10\^9/L and normal marrow differential with \<5% blasts. They were RBC and platelet transfusion independent and no evidence of extramedullary leukemia. CRh was defined as a condition at the post baseline visit, having bone marrow blasts \< 5%, partial hematologic recovery ANC ≥ 0.5x10\^9/L and platelets ≥ 50x10\^9/L, no evidence of extramedullary leukemia and cannot be classified as CR. The blast counts in peripheral blood was ≤ 2%. Relapse: BM blasts ≥ 5%, reappearance or new appearance of extramedullary leukemia, reappearance of significant numbers of peripheral blasts.

    Time frame: From date of achieving CR/CRh until date of confirmed relapse (maximum duration was 58.1 months)

  6. Duration Of Response (DOR)

    DOR: time from date of first CRc (CR+CRp+CRi)/PR until date of first documented relapse for participants who achieved CRc or PR. KM estimate used for analysis. CR: morphologically leukemia-free state, with ANC\> 1x10\^9/L, platelet count ≥ 100x10\^9/L and normal marrow differential with \<5% blasts. They were RBC and platelet transfusion independent and no evidence of extramedullary leukemia. CRp: met all CR criteria except incomplete platelet recovery (\< 100x10\^9/L). CRi: met all CR criteria, except for incomplete hematological recovery with residual neutropenia \< 1x10\^9/L with or without complete platelet recovery. PR: condition with regeneration of normal hematopoietic cells in BM, no detectable blasts, ≥ 50% decrease of blasts in BM aspirate \& total BM blasts of 5-25%. Relapse: BM blasts ≥ 5%, reappearance or new appearance of extramedullary leukemia, reappearance of significant numbers of peripheral blasts and increase in the percentage of blasts in the BM aspirate to \> 25%.

    Time frame: From date of achieving CRc/PR until date of confirmed relapse (maximum duration was 52.1 months)

  7. CR/CRh Rate

    Percentage of participants with CR/CRh was reported. CR: morphologically leukemia-free state, with ANC\> 1x10\^9/L, platelet count ≥ 100x10\^9/L and normal marrow differential with \<5% blasts. They were RBC and platelet transfusion independent and no evidence of extramedullary leukemia. CRh was defined as a condition at the post baseline visit, having bone marrow blasts \< 5%, partial hematologic recovery ANC ≥ 0.5x10\^9/L and platelets ≥ 50x10\^9/L, no evidence of extramedullary leukemia and could be classified as CR. The blast counts in peripheral blood was ≤ 2%.

    Time frame: From the date of randomization up to approximately 74 months

  8. Best Response Rate

    Defined as percentage of participants with CR, CRp, CRi, PR, no response (NR) \& not estimable (NE). CR: morphologically leukemia-free state, with ANC\> 1x10\^9/L, platelet count ≥ 100x10\^9/L \& normal marrow differential with \< 5% blasts. They were RBC \& platelet transfusion independent \& no evidence of extramedullary leukemia. CRp: met all CR criteria except incomplete platelet recovery (\<100x10\^9/L). CRi: met all CR criteria, except incomplete hematological recovery with residual neutropenia \< 1x10\^9/L with/without complete platelet recovery. PR: condition with regeneration of normal hematopoietic cells in BM, no detectable blasts, ≥ 50% decrease of blasts in BM aspirate \& total BM blasts of 5-25%. \<=5% BM blasts if Auer rods are present, no evidence of extramedullary leukemia. Not Estimable (NE): No BM assessed/no myeloblast value, no blast value from peripheral blood or ≤2%, \& no extramedullary leukemia. No Response (NR): Response not categorized as CR, CRp, CRi, PR or NE.

    Time frame: From the date of randomization up to approximately 74 months

  9. Leukemia-Fee Survival (LFS)

    LFS: time from the date of first CRc (CR+CRp+CRi) until the date of documented relapse or death for participants who achieved CRc. CR: morphologically leukemia-free state, with ANC\> 1x10\^9/L, platelet count ≥ 100x10\^9/L and normal marrow differential with \< 5% blasts. They were RBC and platelet transfusion independent and no evidence of extramedullary leukemia. CRp: met all CR criteria except incomplete platelet recovery (\< 100x10\^9/L). CRi: met all CR criteria, except for incomplete hematological recovery with residual neutropenia \< 1x10\^9/L with or without complete platelet recovery. Relapse: BM blasts ≥ 5%, reappearance or new appearance of extramedullary leukemia, reappearance of significant numbers of peripheral blasts.

    Time frame: From first day of achieving first CRc to the first day of confirmed relapse/death (maximum duration was 60.0 months)

  10. Composite Complete Remission (CRc)

    Percentage of participants with CRc (CR+CRp+CRi) was reported. CR: morphologically leukemia-free state, with ANC\> 1x10\^9/L, platelet count ≥ 100x10\^9/L and normal marrow differential with \<5% blasts. They were RBC and platelet transfusion independent and no evidence of extramedullary leukemia. CRp: met all CR criteria except incomplete platelet recovery (\< 100x10\^9/L). CRi: met all CR criteria, except for incomplete hematological recovery with residual neutropenia \< 1x10\^9/L with or without complete platelet recovery.

    Time frame: From the date of randomization up to approximately 74 months

  11. Time to CRc

    Time to CRc (TTCRc) was defined as the time from the date of randomization until the date of first CRc. CRc: Rate of all complete and incomplete remissions (CR + CRp +Cri) CR: morphologically leukemia-free state, with ANC\> 1x10\^9/L, platelet count ≥ 100x10\^9/L and normal marrow differential with \<5% blasts. They were RBC and platelet transfusion independent and no evidence of extramedullary leukemia. CRp: met all CR criteria except incomplete platelet recovery (\< 100x10\^9/L). CRi: met all CR criteria, except for incomplete hematological recovery with residual neutropenia \< 1x10\^9/L with or without complete platelet recovery.

    Time frame: From randomization until date of first CRc (up to approximately 74 months)

  12. Time to CR

    Time to CR (TTCR) was defined as the time from the date of randomization until the date of first CR. CR: morphologically leukemia-free state, with ANC\> 1x10\^9/L, platelet count ≥ 100x10\^9/L and normal marrow differential with \< 5% blasts. They were RBC and platelet transfusion independent and no evidence of extramedullary leukemia.

    Time frame: From randomization until date of first CR (up to approximately 74 months)

  13. Time to Response

    Time to Response (TTR) was defined as the time from the date of randomization until the date of either first response (CRc or PR). CRc: Rate of all complete and incomplete remissions (CR + CRp +Cri) CR: morphologically leukemia-free state, with ANC\> 1x10\^9/L, platelet count ≥ 100x10\^9/L and normal marrow differential with \<5% blasts. They were RBC and platelet transfusion independent and no evidence of extramedullary leukemia. CRp: met all CR criteria except incomplete platelet recovery (\< 100x10\^9/L). CRi: met all CR criteria, except for incomplete hematological recovery with residual neutropenia \< 1x10\^9/L with or without complete platelet recovery. PR: condition with regeneration of normal hematopoietic cells in BM, no detectable blasts, ≥ 50% decrease of blasts in BM aspirate \& total BM blasts of 5-25%.

    Time frame: From randomization until date of first CRc or PR (up to approximately 74 months)

  14. Time to CR/CRh

    Time to CR/CRh (TTCRCRh) was defined as the time from the date of randomization until the date of first CR/CRh. CR: morphologically leukemia-free state, with ANC\> 1x10\^9/L, platelet count ≥ 100x10\^9/L and normal marrow differential with \<5% blasts. They were RBC and platelet transfusion independent and no evidence of extramedullary leukemia. CRh was defined as a condition at the post baseline visit, having bone marrow blasts \< 5%, partial hematologic recovery ANC ≥ 0.5x10\^9/L and platelets ≥ 50x10\^9/L, no evidence of extramedullary leukemia and cannot be classified as CR. The blast counts in peripheral blood was ≤ 2%.

    Time frame: From randomization until date of first CR/CRh (up to approximately 74 months)

  15. Percentage of Participants With Transfusion Conversion and Transfusion Maintenance

    Transfusion conversion rate: Percentage of transfusion dependent participants at baseline period but became transfusion independent at post-baseline period divided by total participants who were transfusion dependent at baseline period. Transfusion maintenance rate: Percentage of transfusion independent participants at baseline period and still maintained transfusion independent at post-baseline period divided by total participants who were transfusion independent at baseline period. Baseline transfusion status: Participants were classified as transfusion independent if there were no RBC or platelet transfusions within 28 days prior to first dose to 28 days after first dose; otherwise classified as transfusion dependent. Post baseline transfusion status: Participants on treatment ≥ 84 days were classified as transfusion independent, if consecutive 56 days without any RBC or platelet transfusion; otherwise classified as transfusion dependent

    Time frame: Baseline up to approximately 74 months

  16. Percentage of Participants With Transplantation Rate

    Transplantation rate is defined as the percentage of participants undergoing Hematopoietic stem cell transplant (HSCT) during the study period.

    Time frame: Baseline up to approximately 74 months

  17. Change From Baseline in Brief Fatigue Inventory (BFI)

    The BFI is a screening tool designed to assess the severity and impact of fatigue on daily functioning of participants with cancer during the 24 hours. There are 9 items on the scale. The first three questions ask participants to rate their fatigues on a scale from 0 (no fatigue) - 10 (as bad as you can imagine), with higher scores indicating worse outcome. The remaining six questions ask participants to rate how much fatigue has interfered with their daily activities on a scale from 0 (Does not interfere) to 10 (Completely interferes). A global fatigue score can be obtained by averaging all the items on the BFI, ranging between 0 to 10; a higher BFI fatigue score indicates worse outcome. The global BFI scores were calculated only if at least 5 of the 9 items are answered.

    Time frame: Baseline, End of treatment (63 months)

  18. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE could therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. TEAE was defined as an adverse event observed after starting administration of the study drug.

    Time frame: From the date of first dose up to approximately 74 months

  19. Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Scores

    The ECOG Scale was used to assess performance status. Number of participants with each grade was reported. Grade Description: 0: Fully active, able to carry on all pre-disease performance without restriction. 1. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work. 2. Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours. 3. Capable of only limited self-care, confined to bed or chair more than 50% of waking hours. 4. Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. 5. Dead.

    Time frame: Baseline, end of treatment visit (63 months)

  20. Pharmacokinetics (PK) of Gilteritinib in Chinese PK Cohort: Area Under the Concentration Curve at 24 Hours (AUC24)

    AUC24 was derived from the PK samples collected.

    Time frame: Cycle 1 Day 1(C1D1): predose, 0.5, 1, 2, 3, 4, 6, 10, 24 hour post dose, Cycle 1 Day 15(C1D15): predose, 0.5, 1, 2, 3, 4, 6, 10, 24 hour post dose

  21. PK of Gilteritinib in Chinese PK Cohort: Maximum Concentration (Cmax)

    Cmax was derived from the PK samples collected.

    Time frame: C1D1: predose, 0.5, 1, 2, 3, 4, 6, 10, 24 hour post dose, C1D15: predose, 0.5, 1, 2, 3, 4, 6, 10, 24 hour post dose

  22. PK of Gilteritinib: Observed Trough Concentration (Ctrough)

    Ctrough was derived from the PK samples collected.

    Time frame: Predose on C1D15

  23. PK of Gilteritinib in Chinese PK Cohort: Time to Maximum Concentration (Tmax)

    tmax was derived from the PK samples collected.

    Time frame: C1D1: predose, 0.5, 1, 2, 3, 4, 6, 10, 24 hours (+/- 20 minutes) post dose, C1D15: predose, 0.5, 1, 2, 3, 4, 6, 10, 24 hours (+/- 20 minutes) post dose

  24. Ctrough Concentration of Gilteritinib

    Concentrations below the lower limit of quantification (0.5 ng/mL) were set to zero.

    Time frame: Predose C1D8, C1D15, Day 1 of each cycle from C2 to C65, C67D1,C68D1,C69D1,C70D1

06

Results

Posted Jan 14, 2025

Participant flow

Participants with FMS-like tyrosine kinase 3 (FLT3) mutations with relapsed or refractory Acute Myeloid Leukemia (AML) after first-line therapy were enrolled for this study. 21 participants from six china sites were included in Giltertinib PK cohort.

Treatment Period (Upto 1917 Days)
Participant flow — Treatment Period (Upto 1917 Days)
MilestoneGilteritinibSalvage Chemotherapy
Started137139
Lodac027
Mec042
Flag070
Chinese pk cohort210
Completed026
Not completed137113
Withdrew: Adverse event89
Withdrew: Death198
Withdrew: Miscellaneous120
Withdrew: Disease relapse415
Withdrew: Physician decision510
Withdrew: Withdrawal by subject1028
Withdrew: Protocol violation41
Withdrew: Progressive disease189
Withdrew: Lack of efficacy2043
Long Term Follow-up (Up to 1232 Days)
Participant flow — Long Term Follow-up (Up to 1232 Days)
MilestoneGilteritinibSalvage Chemotherapy
Started100105
Completed912
Not completed9193
Withdrew: Miscellaneous43
Withdrew: Withdrawal by subject58
Withdrew: Lost to follow-up67
Withdrew: Death7675
Cross Over Extension (COE) Period
Participant flow — Cross Over Extension (COE) Period
MilestoneGilteritinibSalvage Chemotherapy
Started00
Completed00
Not completed00

Outcome measures

PrimaryOverall Survival (OS)

OS was defined as the time from the date of randomization to the date of death due to any cause. Participants who were still alive or lost to follow up were censored at the time they were last known to be alive. Kaplan-Meier (KM) estimates was used for analysis.

Time frame:
From the date of randomization up to the date of death (up to approximatley 74 months)
Reported as:
Median · months
Overall Survival (OS)
monthsGilteritinibSalvage Chemotherapy
Overall Survival (OS)10.3 (8.8 to 12.7)5.4 (4.1 to 8.1)
Statistical analysis
  • Gilteritinib vs Salvage Chemotherapy · Log Rank · p = 0.00152 · Hazard ratio (hr): 0.612 · 95% CI 0.451 to 0.832Based on Cox proportional hazard model. Assuming proportional hazards, an HR \< 1 indicates a reduction in hazard rate where the numerator is the Gilteritinib arm and the denominator is the Salvage chemotherapy arm.
SecondaryEvent-Free Survival (EFS)

EFS: time from the date of randomization until the date of documented relapse, treatment failure, death, reported off treatment relapse or new AML therapy start whichever occued first, including the long-term follow-up data. KM estimate was used for analysis. Relapse was defined as documentation of any of following events: * Bone marrow (BM) blasts ≥ 5% (not attributable to regenerating BM) * Reappearance or new appearance of extramedullary leukemia * Reappearance of significant numbers of peripheral blasts Treatment failure: Treatment failure was defined as participant who ends treatment without having a previous response of CR, CR with incomplete platelet recovery (CRp) and CR with incomplete hematological recover (CRi).

Time frame:
From the date of randomization up to the date of documented relapse, treatment failure or death from any cause, off-treatment relapse and start of new AML therapy (up to approximately 74 months)
Reported as:
Median · months
Event-Free Survival (EFS)
monthsGilteritinibSalvage Chemotherapy
Event-Free Survival (EFS)2.1 (0.1 to 3.2)0.6 (0.2 to 1.2)
Statistical analysis
  • Gilteritinib vs Salvage Chemotherapy · Log Rank · p = 0.00005 · Hazard ratio (hr): 0.589 · 95% CI 0.438 to 0.792Based on Cox proportional hazard model. Assuming proportional hazards, an HR \< 1 indicates a reduction in hazard rate where the numerator is the Gilteritinib arm and the denominator is the Salvage chemotherapy arm.
SecondaryComplete Remission (CR) Rate

Percentage of participants with CR were reported. CR: morphologically leukemia-free state, with absolute neutrophil count (ANC) \> 1x10\^9 per liter (1x10\^9/L), platelet count ≥ 100x10\^9/L and normal marrow differential with \<5% blasts. They were red blood cell (RBC) and platelet transfusion independent and no evidence of extramedullary leukemia or Auer rods was necessary.

Time frame:
From the date of randomization up to approximately 74 months
Reported as:
Number · Percentage of participants
Complete Remission (CR) Rate
Percentage of participantsGilteritinibSalvage Chemotherapy
Complete Remission (CR) Rate20.4 (14.0 to 28.2)11.5 (6.7 to 18.0)
Statistical analysis
  • Gilteritinib vs Salvage Chemotherapy · Cochran-Mantel-Haenszel · p = 0.04256 · Treatment difference: 8.9 · 95% CI 0.3 to 17.5Stratification factors: first-line AML therapy \& preselected salvage chemotherapy/IRT response. Treatment difference based on stratification factors.
SecondaryDuration of CR

Duration of CR: time from the date of achieving first CR until date of first documented relapse for participants who achieved CR. KM estimate was used for analysis. CR: morphologically leukemia-free state, with ANC\> 1x10\^9/L, platelet count ≥ 100x10\^9/L and normal marrow differential with \< 5% blasts. They were RBC and platelet transfusion independent and no evidence of extramedullary leukemia. Relapse was defined as documentation of any of following events: * BM blasts ≥ 5% (not attributable to regenerating BM) * Reappearance or new appearance of extramedullary leukemia * Reappearance of significant numbers of peripheral blasts

Time frame:
From date of achieving CR until date of confirmed relapse (maximum duration was 53.4 months )
Reported as:
Median · months
Duration of CR
monthsGilteritinibSalvage Chemotherapy
Duration of CR24.0 (4.6 to NA)NA (1.0 to NA)
Statistical analysis
  • Gilteritinib vs Salvage Chemotherapy · Log Rank · p = 0.88710 · Hazard ratio (hr): 1.163 · 95% CI 0.131 to 10.338Based on Cox proportional hazard model. Assuming proportional hazards, an HR \< 1 indicates a reduction in hazard rate where the numerator is the Gilteritinib arm and the denominator is the Salvage chemotherapy arm.
SecondaryDuration of Composite Complete Remission (CRc)

Duration of CRc: time from date of achieving first CRc until date of first documented relapse for participants who achieved CRc. KM estimate was used for analysis. CRc: rate of all complete \& incomplete remissions \[CR + CRp + CRi\]. CR: morphologically leukemia-free state, with ANC\> 1x10\^9/L, platelet count ≥ 100x10\^9/L and normal marrow differential with \<5% blasts. They were RBC and platelet transfusion independent and no evidence of extramedullary leukemia. CRp: met all CR criteria except incomplete platelet recovery (\< 100x10\^9/L). CRi: met all CR criteria, except for incomplete hematological recovery with residual neutropenia \< 1x10\^9/L with or without complete platelet recovery. Relapse: BM blasts ≥ 5%, reappearance or new appearance of extramedullary leukemia, reappearance of significant numbers of peripheral blasts.

Time frame:
From date of achieving CRc until date of confirmed relapse (maximum duration was 60 months)
Reported as:
Median · months
Duration of Composite Complete Remission (CRc)
monthsGilteritinibSalvage Chemotherapy
Duration of Composite Complete Remission (CRc)4.1 (2.8 to 5.6)NA (NA to NA)
Statistical analysis
  • Gilteritinib vs Salvage Chemotherapy · Log Rank · p = 0.55969 · Hazard ratio (hr): 0.710 · 95% CI 0.209 to 2.414Based on Cox proportional hazard model. Assuming proportional hazards, an HR \< 1 indicates a reduction in hazard rate where the numerator is the Gilteritinib arm and the denominator is the Salvage chemotherapy arm.
SecondaryDuration of CR/Complete Remission With Partial Hematologic Recovery (CRh)

Duration of CR/CRh: time from date of achieving first CR/CRh until date of first documented relapse for participants who achieved CR/CRh. KM estimate was used for analysis. CR: morphologically leukemia-free state, with ANC\> 1x10\^9/L, platelet count ≥ 100x10\^9/L and normal marrow differential with \<5% blasts. They were RBC and platelet transfusion independent and no evidence of extramedullary leukemia. CRh was defined as a condition at the post baseline visit, having bone marrow blasts \< 5%, partial hematologic recovery ANC ≥ 0.5x10\^9/L and platelets ≥ 50x10\^9/L, no evidence of extramedullary leukemia and cannot be classified as CR. The blast counts in peripheral blood was ≤ 2%. Relapse: BM blasts ≥ 5%, reappearance or new appearance of extramedullary leukemia, reappearance of significant numbers of peripheral blasts.

Time frame:
From date of achieving CR/CRh until date of confirmed relapse (maximum duration was 58.1 months)
Reported as:
Median · months
Duration of CR/Complete Remission With Partial Hematologic Recovery (CRh)
monthsGilteritinibSalvage Chemotherapy
Duration of CR/Complete Remission With Partial Hematologic Recovery (CRh)5.6 (2.8 to 24.0)NA (NA to NA)
Statistical analysis
  • Gilteritinib vs Salvage Chemotherapy · Log Rank · p = 0.66261 · Hazard ratio (hr): 1.583 · 95% CI 0.192 to 13.048Based on Cox proportional hazard model. Assuming proportional hazards, an HR \< 1 indicates a reduction in hazard rate where the numerator is the Gilteritinib arm and the denominator is the Salvage chemotherapy arm.
SecondaryDuration Of Response (DOR)

DOR: time from date of first CRc (CR+CRp+CRi)/PR until date of first documented relapse for participants who achieved CRc or PR. KM estimate used for analysis. CR: morphologically leukemia-free state, with ANC\> 1x10\^9/L, platelet count ≥ 100x10\^9/L and normal marrow differential with \<5% blasts. They were RBC and platelet transfusion independent and no evidence of extramedullary leukemia. CRp: met all CR criteria except incomplete platelet recovery (\< 100x10\^9/L). CRi: met all CR criteria, except for incomplete hematological recovery with residual neutropenia \< 1x10\^9/L with or without complete platelet recovery. PR: condition with regeneration of normal hematopoietic cells in BM, no detectable blasts, ≥ 50% decrease of blasts in BM aspirate \& total BM blasts of 5-25%. Relapse: BM blasts ≥ 5%, reappearance or new appearance of extramedullary leukemia, reappearance of significant numbers of peripheral blasts and increase in the percentage of blasts in the BM aspirate to \> 25%.

Time frame:
From date of achieving CRc/PR until date of confirmed relapse (maximum duration was 52.1 months)
Reported as:
Median · months
Duration Of Response (DOR)
monthsGilteritinibSalvage Chemotherapy
Duration Of Response (DOR)3.7 (2.5 to 4.7)NA (1.2 to NA)
Statistical analysis
  • Gilteritinib vs Salvage Chemotherapy · Log Rank · p = 0.55731 · Hazard ratio (hr): 0.756 · 95% CI 0.286 to 1.999Based on Cox proportional hazard model. Assuming proportional hazards, an HR \< 1 indicates a reduction in hazard rate where the numerator is the Gilteritinib arm and the denominator is the Salvage chemotherapy arm.
SecondaryCR/CRh Rate

Percentage of participants with CR/CRh was reported. CR: morphologically leukemia-free state, with ANC\> 1x10\^9/L, platelet count ≥ 100x10\^9/L and normal marrow differential with \<5% blasts. They were RBC and platelet transfusion independent and no evidence of extramedullary leukemia. CRh was defined as a condition at the post baseline visit, having bone marrow blasts \< 5%, partial hematologic recovery ANC ≥ 0.5x10\^9/L and platelets ≥ 50x10\^9/L, no evidence of extramedullary leukemia and could be classified as CR. The blast counts in peripheral blood was ≤ 2%.

Time frame:
From the date of randomization up to approximately 74 months
Reported as:
Number · Percentage of participants
CR/CRh Rate
Percentage of participantsGilteritinibSalvage Chemotherapy
CR/CRh Rate32.1 (24.4 to 40.6)14.4 (9.0 to 21.3)
Statistical analysis
  • Gilteritinib vs Salvage Chemotherapy · Cochran-Mantel-Haenszel · p = 0.00049 · Treatment difference: 17.7 · 95% CI 7.9 to 27.5Stratification factors: first-line AML therapy \& preselected salvage chemotherapy/IRT response. Treatment difference based on stratification factors.
SecondaryBest Response Rate

Defined as percentage of participants with CR, CRp, CRi, PR, no response (NR) \& not estimable (NE). CR: morphologically leukemia-free state, with ANC\> 1x10\^9/L, platelet count ≥ 100x10\^9/L \& normal marrow differential with \< 5% blasts. They were RBC \& platelet transfusion independent \& no evidence of extramedullary leukemia. CRp: met all CR criteria except incomplete platelet recovery (\<100x10\^9/L). CRi: met all CR criteria, except incomplete hematological recovery with residual neutropenia \< 1x10\^9/L with/without complete platelet recovery. PR: condition with regeneration of normal hematopoietic cells in BM, no detectable blasts, ≥ 50% decrease of blasts in BM aspirate \& total BM blasts of 5-25%. \<=5% BM blasts if Auer rods are present, no evidence of extramedullary leukemia. Not Estimable (NE): No BM assessed/no myeloblast value, no blast value from peripheral blood or ≤2%, \& no extramedullary leukemia. No Response (NR): Response not categorized as CR, CRp, CRi, PR or NE.

Time frame:
From the date of randomization up to approximately 74 months
Reported as:
Number · Percentage of participants
Best Response Rate
Percentage of participantsGilteritinibSalvage Chemotherapy
CR20.411.5
CRp13.10.7
CRi19.710.1
PR14.65.0
NR27.734.5
NE4.438.1
SecondaryLeukemia-Fee Survival (LFS)

LFS: time from the date of first CRc (CR+CRp+CRi) until the date of documented relapse or death for participants who achieved CRc. CR: morphologically leukemia-free state, with ANC\> 1x10\^9/L, platelet count ≥ 100x10\^9/L and normal marrow differential with \< 5% blasts. They were RBC and platelet transfusion independent and no evidence of extramedullary leukemia. CRp: met all CR criteria except incomplete platelet recovery (\< 100x10\^9/L). CRi: met all CR criteria, except for incomplete hematological recovery with residual neutropenia \< 1x10\^9/L with or without complete platelet recovery. Relapse: BM blasts ≥ 5%, reappearance or new appearance of extramedullary leukemia, reappearance of significant numbers of peripheral blasts.

Time frame:
From first day of achieving first CRc to the first day of confirmed relapse/death (maximum duration was 60.0 months)
Reported as:
Median · months
Leukemia-Fee Survival (LFS)
monthsGilteritinibSalvage Chemotherapy
Leukemia-Fee Survival (LFS)3.9 (2.8 to 5.4)6.9 (2.9 to 10.4)
Statistical analysis
  • Gilteritinib vs Salvage Chemotherapy · Log Rank · p = 0.56944 · Hazard ratio (hr): 0.857 · 95% CI 0.494 to 1.487Based on Cox proportional hazard model. Assuming proportional hazards, an HR \< 1 indicates a reduction in hazard rate where the numerator is the Gilteritinib arm and the denominator is the Salvage chemotherapy arm.
SecondaryComposite Complete Remission (CRc)

Percentage of participants with CRc (CR+CRp+CRi) was reported. CR: morphologically leukemia-free state, with ANC\> 1x10\^9/L, platelet count ≥ 100x10\^9/L and normal marrow differential with \<5% blasts. They were RBC and platelet transfusion independent and no evidence of extramedullary leukemia. CRp: met all CR criteria except incomplete platelet recovery (\< 100x10\^9/L). CRi: met all CR criteria, except for incomplete hematological recovery with residual neutropenia \< 1x10\^9/L with or without complete platelet recovery.

Time frame:
From the date of randomization up to approximately 74 months
Reported as:
Number · Percentage of participants
Composite Complete Remission (CRc)
Percentage of participantsGilteritinibSalvage Chemotherapy
Composite Complete Remission (CRc)53.3 (44.6 to 61.9)22.3 (15.7 to 30.1)
Statistical analysis
  • Gilteritinib vs Salvage Chemotherapy · Cochran-Mantel-Haenszel · p = <0.00001 · Treatment difference: 31.2 · 95% CI 20.2 to 42.3Stratification factors: first-line AML therapy \& preselected salvage chemotherapy/IRT response. Treatment difference based on stratification factors.
SecondaryTime to CRc

Time to CRc (TTCRc) was defined as the time from the date of randomization until the date of first CRc. CRc: Rate of all complete and incomplete remissions (CR + CRp +Cri) CR: morphologically leukemia-free state, with ANC\> 1x10\^9/L, platelet count ≥ 100x10\^9/L and normal marrow differential with \<5% blasts. They were RBC and platelet transfusion independent and no evidence of extramedullary leukemia. CRp: met all CR criteria except incomplete platelet recovery (\< 100x10\^9/L). CRi: met all CR criteria, except for incomplete hematological recovery with residual neutropenia \< 1x10\^9/L with or without complete platelet recovery.

Time frame:
From randomization until date of first CRc (up to approximately 74 months)
Reported as:
Median · months
Time to CRc
monthsGilteritinibSalvage Chemotherapy
Time to CRc1.8 (1 to 8)1.0 (1 to 2)
SecondaryTime to CR

Time to CR (TTCR) was defined as the time from the date of randomization until the date of first CR. CR: morphologically leukemia-free state, with ANC\> 1x10\^9/L, platelet count ≥ 100x10\^9/L and normal marrow differential with \< 5% blasts. They were RBC and platelet transfusion independent and no evidence of extramedullary leukemia.

Time frame:
From randomization until date of first CR (up to approximately 74 months)
Reported as:
Median · months
Time to CR
monthsGilteritinibSalvage Chemotherapy
Time to CR3.7 (1 to 19)1.1 (1 to 2)
SecondaryTime to Response

Time to Response (TTR) was defined as the time from the date of randomization until the date of either first response (CRc or PR). CRc: Rate of all complete and incomplete remissions (CR + CRp +Cri) CR: morphologically leukemia-free state, with ANC\> 1x10\^9/L, platelet count ≥ 100x10\^9/L and normal marrow differential with \<5% blasts. They were RBC and platelet transfusion independent and no evidence of extramedullary leukemia. CRp: met all CR criteria except incomplete platelet recovery (\< 100x10\^9/L). CRi: met all CR criteria, except for incomplete hematological recovery with residual neutropenia \< 1x10\^9/L with or without complete platelet recovery. PR: condition with regeneration of normal hematopoietic cells in BM, no detectable blasts, ≥ 50% decrease of blasts in BM aspirate \& total BM blasts of 5-25%.

Time frame:
From randomization until date of first CRc or PR (up to approximately 74 months)
Reported as:
Median · months
Time to Response
monthsGilteritinibSalvage Chemotherapy
Time to Response1.0 (1 to 7)1.0 (1 to 2)
SecondaryTime to CR/CRh

Time to CR/CRh (TTCRCRh) was defined as the time from the date of randomization until the date of first CR/CRh. CR: morphologically leukemia-free state, with ANC\> 1x10\^9/L, platelet count ≥ 100x10\^9/L and normal marrow differential with \<5% blasts. They were RBC and platelet transfusion independent and no evidence of extramedullary leukemia. CRh was defined as a condition at the post baseline visit, having bone marrow blasts \< 5%, partial hematologic recovery ANC ≥ 0.5x10\^9/L and platelets ≥ 50x10\^9/L, no evidence of extramedullary leukemia and cannot be classified as CR. The blast counts in peripheral blood was ≤ 2%.

Time frame:
From randomization until date of first CR/CRh (up to approximately 74 months)
Reported as:
Median · months
Time to CR/CRh
monthsGilteritinibSalvage Chemotherapy
Time to CR/CRh2.8 (1 to 11)1.1 (1 to 2)
SecondaryPercentage of Participants With Transfusion Conversion and Transfusion Maintenance

Transfusion conversion rate: Percentage of transfusion dependent participants at baseline period but became transfusion independent at post-baseline period divided by total participants who were transfusion dependent at baseline period. Transfusion maintenance rate: Percentage of transfusion independent participants at baseline period and still maintained transfusion independent at post-baseline period divided by total participants who were transfusion independent at baseline period. Baseline transfusion status: Participants were classified as transfusion independent if there were no RBC or platelet transfusions within 28 days prior to first dose to 28 days after first dose; otherwise classified as transfusion dependent. Post baseline transfusion status: Participants on treatment ≥ 84 days were classified as transfusion independent, if consecutive 56 days without any RBC or platelet transfusion; otherwise classified as transfusion dependent

Time frame:
Baseline up to approximately 74 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Transfusion Conversion and Transfusion Maintenance
Percentage of participantsGilteritinib
Transfusion Conversion Rate42.7
Transfusion Maintenance Rate70.8
SecondaryPercentage of Participants With Transplantation Rate

Transplantation rate is defined as the percentage of participants undergoing Hematopoietic stem cell transplant (HSCT) during the study period.

Time frame:
Baseline up to approximately 74 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Transplantation Rate
Percentage of participantsGilteritinibSalvage Chemotherapy
Percentage of Participants With Transplantation Rate22.6 (15.9 to 30.6)7.9 (4.0 to 13.7)
Statistical analysis
  • Gilteritinib vs Salvage Chemotherapy · Cochran-Mantel-Haenszel · p = 0.00055 · Treatment difference: 14.7 · 95% CI 6.5 to 22.8Stratification factors: first-line AML therapy \& preselected salvage chemotherapy/IRT response. Treatment difference based on stratification factors.
SecondaryChange From Baseline in Brief Fatigue Inventory (BFI)

The BFI is a screening tool designed to assess the severity and impact of fatigue on daily functioning of participants with cancer during the 24 hours. There are 9 items on the scale. The first three questions ask participants to rate their fatigues on a scale from 0 (no fatigue) - 10 (as bad as you can imagine), with higher scores indicating worse outcome. The remaining six questions ask participants to rate how much fatigue has interfered with their daily activities on a scale from 0 (Does not interfere) to 10 (Completely interferes). A global fatigue score can be obtained by averaging all the items on the BFI, ranging between 0 to 10; a higher BFI fatigue score indicates worse outcome. The global BFI scores were calculated only if at least 5 of the 9 items are answered.

Time frame:
Baseline, End of treatment (63 months)
Reported as:
Mean · Scores on scale
Change From Baseline in Brief Fatigue Inventory (BFI)
Scores on scaleGilteritinibSalvage Chemotherapy
Change From Baseline in Brief Fatigue Inventory (BFI)1.42 ± 2.990.75 ± 2.92
Statistical analysis
  • Gilteritinib vs Salvage Chemotherapy · ANCOVA · p = 0.14841 (Analysis of covariance (ANCOVA) including treatment as a fixed factor, baseline score, response to first-line AML therapy and preselected salvage chemotherapy per IRT as covariates. LS Mean difference was estimated using chemotherapy as control.) · Least square mean difference: 0.6
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE could therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. TEAE was defined as an adverse event observed after starting administration of the study drug.

Time frame:
From the date of first dose up to approximately 74 months
Reported as:
Number · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsGilteritinibSalvage Chemotherapy
Number of Participants With Treatment Emergent Adverse Events (TEAEs)134119
SecondaryNumber of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Scores

The ECOG Scale was used to assess performance status. Number of participants with each grade was reported. Grade Description: 0: Fully active, able to carry on all pre-disease performance without restriction. 1. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work. 2. Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours. 3. Capable of only limited self-care, confined to bed or chair more than 50% of waking hours. 4. Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. 5. Dead.

Time frame:
Baseline, end of treatment visit (63 months)
Reported as:
Number · Participants
Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Scores
ParticipantsGilteritinibSalvage Chemotherapy
Grade 0 at baseline3537
Grade 1 at baseline6564
Grade 2 at baseline3418
Grade 3 at baseline00
Grade 4 at baseline00
Grade 5 at baseline00
Grade 0 at End of Treatment1726
Grade 1 at End of Treatment3639
Grade 2 at End of Treatment1921
Grade 3 at End of Treatment106
Grade 4 at End of Treatment12
Grade 5 at End of Treatment00
SecondaryPharmacokinetics (PK) of Gilteritinib in Chinese PK Cohort: Area Under the Concentration Curve at 24 Hours (AUC24)

AUC24 was derived from the PK samples collected.

Time frame:
Cycle 1 Day 1(C1D1): predose, 0.5, 1, 2, 3, 4, 6, 10, 24 hour post dose, Cycle 1 Day 15(C1D15): predose, 0.5, 1, 2, 3, 4, 6, 10, 24 hour post dose
Reported as:
Mean · nanogram*hour per milliliters(ng*h/mL)
Pharmacokinetics (PK) of Gilteritinib in Chinese PK Cohort: Area Under the Concentration Curve at 24 Hours (AUC24)
nanogram*hour per milliliters(ng*h/mL)Gilteritinib
C1D13230 ± 1970
C1D1510000 ± 6670
SecondaryPK of Gilteritinib in Chinese PK Cohort: Maximum Concentration (Cmax)

Cmax was derived from the PK samples collected.

Time frame:
C1D1: predose, 0.5, 1, 2, 3, 4, 6, 10, 24 hour post dose, C1D15: predose, 0.5, 1, 2, 3, 4, 6, 10, 24 hour post dose
Reported as:
Mean · ng/mL
PK of Gilteritinib in Chinese PK Cohort: Maximum Concentration (Cmax)
ng/mLGilteritinib
C1D1206 ± 112
C1D15536 ± 323
SecondaryPK of Gilteritinib: Observed Trough Concentration (Ctrough)

Ctrough was derived from the PK samples collected.

Time frame:
Predose on C1D15
Reported as:
Mean · ng/mL
PK of Gilteritinib: Observed Trough Concentration (Ctrough)
ng/mLGilteritinib
PK of Gilteritinib: Observed Trough Concentration (Ctrough)323 ± 222
SecondaryPK of Gilteritinib in Chinese PK Cohort: Time to Maximum Concentration (Tmax)

tmax was derived from the PK samples collected.

Time frame:
C1D1: predose, 0.5, 1, 2, 3, 4, 6, 10, 24 hours (+/- 20 minutes) post dose, C1D15: predose, 0.5, 1, 2, 3, 4, 6, 10, 24 hours (+/- 20 minutes) post dose
Reported as:
Median · hours
PK of Gilteritinib in Chinese PK Cohort: Time to Maximum Concentration (Tmax)
hoursGilteritinib
Cycle 1 Day 14.00 (2.00 to 24.1)
Cycle 1 Day 153.85 (1.00 to 24.3)
SecondaryCtrough Concentration of Gilteritinib

Concentrations below the lower limit of quantification (0.5 ng/mL) were set to zero.

Time frame:
Predose C1D8, C1D15, Day 1 of each cycle from C2 to C65, C67D1,C68D1,C69D1,C70D1
Reported as:
Mean · ng/mL
Ctrough Concentration of Gilteritinib
ng/mLGilteritinib
C1D8310 ± 177
CID15367 ± 243
C2D1425 ± 305
C3D1457 ± 358
C4D1420 ± 428
C5D1407 ± 487
C6D1284 ± 275
C7D1370 ± 477
C8D1328 ± 323
C9D1351 ± 381
C10D1322 ± 383
C11D1336 ± 426
C12D1460 ± 703
C13D1368 ± 409
C14D1386 ± 449
C15D1396 ± 541
C16D1200 ± 116
C17D1228 ± 138
C18D1201 ± 143
C19D1231 ± 270
C20D1241 ± 190
C21D1221 ± 112
C22D1238 ± 149
C23D1152 ± 137
C24D1188 ± 141
C25D1192 ± 137
C26D1264 ± 138
C27D1199 ± 145
C28D1243 ± 141
C29D1184 ± 138
C30D1340 ± 472
C31D1426 ± 606
C32D1301 ± 395
C33D1431 ± 646
C34D1405 ± 590
C35D1298 ± 420
C36D1264 ± 343
C37D1437 ± 823
C38D178.0 ± 76.3
C39D1107 ± 91.3
C40D1114 ± 59.2
C41D1152 ± 123
C42D1128 ± 150
C43D196.9 ± 114
C44D1148 ± 145
C45D1166 ± 97.9
C46D1105 ± 127
C47D1116 ± 104
C48D1131 ± 107
C49D174.4 ± 82.0
C50D1134 ± 119
C51D1130 ± 136
C52D193.4 ± 114
C53D1148 ± 188
C54D1166 ± 246
C55D1129 ± 169
C56D1157 ± 227
C57D1380
C58D1338
C59D1451
C60D1362
C61D1292
C62D1287
C63D1411
C65D1362
C67D1326
C68D1584
C69D1345
C70D1313

Adverse events

Collected over All-cause mortality: From randomization up to 74 months AEs: From first dose up to 74 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gilteritinib97/137 (70.8%)102/134 (76.1%)133/134 (99.3%)
Salvage Chemotherapy85/139 (61.2%)71/119 (59.7%)113/119 (95%)
Most frequent serious events
Showing 10 of 134
Most frequent serious events
EventGilteritinibSalvage Chemotherapy
Febrile neutropeniaBlood and lymphatic system disorders29/13425/119
PneumoniaInfections and infestations24/1348/119
SepsisInfections and infestations9/13415/119
AnaemiaBlood and lymphatic system disorders14/1341/119
PyrexiaGeneral disorders12/1340/119
ThrombocytopeniaBlood and lymphatic system disorders11/1341/119
Neutropenic sepsisInfections and infestations8/1344/119
Skin infectionInfections and infestations7/1340/119
Septic shockInfections and infestations5/1345/119
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/1345/119
Most frequent other events
Showing 10 of 94
Most frequent other events
EventGilteritinibSalvage Chemotherapy
AnaemiaBlood and lymphatic system disorders99/13479/119
Blood lactate dehydrogenase increasedInvestigations61/13422/119
White blood cell count decreasedInvestigations55/13451/119
HypokalaemiaMetabolism and nutrition disorders57/13445/119
Platelet count decreasedInvestigations55/13450/119
ThrombocytopeniaBlood and lymphatic system disorders56/13444/119
Aspartate aminotransferase increasedInvestigations56/13419/119
PyrexiaGeneral disorders54/13445/119
Neutrophil count decreasedInvestigations51/13444/119
Alanine aminotransferase increasedInvestigations49/13423/119

Baseline characteristics

Intent-to-treat analysis Set (ITT) : The ITT consisted of all participants who were randomized.

Age, Continuous
Age, Continuous(Years)GilteritinibSalvage ChemotherapyTotal
Mean46.9 ± 16.246.2 ± 15.146.6 ± 15.7
Sex: Female, Male
Sex: Female, Male(Participants)GilteritinibSalvage ChemotherapyTotal
Female7670146
Male6169130
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)GilteritinibSalvage ChemotherapyTotal
Hispanic or Latino000
Not Hispanic or Latino136139275
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)GilteritinibSalvage ChemotherapyTotal
American Indian or Alaska Native000
Asian123120243
Native Hawaiian or Other Pacific Islander000
Black or African American000
White141933
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)GilteritinibSalvage ChemotherapyTotal
China9092182
Russia141933
Malaysia151429
Thailand141024
Singapore448
Response to First-Line Therapy
Response to First-Line Therapy(Participants)GilteritinibSalvage ChemotherapyTotal
Relapse within 6 months after allogeneic HSCT145
Relapse after 6 months after allogeneic HSCT224
Primary refractory without HSCT8081161
Relapse within 6 months after CRc and no HSCT312960
Relapse after 6 months after CRc and no HSCT232346
Preselected Salvage Chemotherapy
Preselected Salvage Chemotherapy(Participants)GilteritinibSalvage ChemotherapyTotal
High intensity chemotherapy110112222
Low intensity chemotherapy272754
07

Study locations

49 sites
  • Site CN103
    Beijing, China
  • Site CN108
    Beijing, China
  • Site CN109
    Beijing, China
  • Site CN110
    Beijing, China
  • Site CN131
    Beijing, China
  • Site CN116
    Changchun, China
  • Site CN120
    Changsha, China
  • Site CN119
    Fuzhou, China
  • Site CN102
    Guangzhou, China
  • Site CN114
    Guangzhou, China
  • Site CN121
    Guangzhou, China
  • Site CN130
    Guiyang, China
  • Site CN107
    Hangzhou, China
  • Site CN118
    Hefei, China
  • Site CN123
    Huangpu Qu, China
  • Site CN117
    Jinan, China
  • Site CN133
    Lanzhou, China
  • Site CN128
    Nanjing, China
  • Site CN106
    Qingdao, China
  • Site CN126
    Shanghai, China
  • Site CN129
    Shanghai, China
  • Site CN125
    Shenyang, China
  • Site CN101
    Tianjin, China
  • Site CN105
    Wuhan, China
  • Site CN122
    Xi'an, China
  • Site CN132
    Zhangzhou, China
  • Site CN113
    Zhengzhou, China
  • Site CN136
    Zhengzhou, China
  • Site MY306
    Ampang, Malaysia
  • Site MY305
    George Town, Malaysia
  • Site MY301
    Johor Bahru, Malaysia
  • Site MY304
    Kota Kinabalu, Malaysia
  • Site MY302
    Kuala Lumpur, Malaysia
  • Site MY303
    Pulau Pinang, Malaysia
  • Site RU506
    Kemerovo, Russia
  • Site RU504
    Krasnoyarsk, Russia
  • Site RU508
    Moscow, Russia
  • Site RU509
    Moscow, Russia
  • Site RU501
    Saint Petersburg, Russia
  • Site RU502
    Saint Petersburg, Russia
  • Site RU507
    Saint Petersburg, Russia
  • Site SG401
    Singapore, Singapore
  • Site SG402
    Singapore, Singapore
  • Site SG403
    Singapore, Singapore
  • Site TH203
    Bangkok, Thailand
  • Site TH205
    Bangkok, Thailand
  • Site TH204
    Chiang Mai, Thailand
  • Site TH201
    Khon Kaen, Thailand
  • Site TH202
    Khon Kaen, Thailand
08

References and documents

Publications

  • Perl AE, Levis MJ, Wei AH, Kim HJ, Cheong JW, Li J, Bondarenko S, Yokoyama H, Hosono N, Hasabou N, Elsouda D, Ariza J, An JJ, Wang J. Timing of response in patients with relapsed/refractory FLT3 mut+ acute myeloid leukemia treated with gilteritinib. Blood Neoplasia. 2026 Jul 13;3(4):100270. doi: 10.1016/j.bneo.2026.100270. eCollection 2026 Nov. PubMed 42668697 ↗
  • Jiang B, Li J, Liu L, Du X, Jiang H, Hu J, Zeng X, Sakatani T, Kosako M, Deng Y, Girshova L, Bondarenko S, Lee LWL, Khuhapinant A, Martynova E, Hasabou N, Wang J. Gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia: a regional analysis of COMMODORE in China, South-East Asia, and Russia. Ann Hematol. 2025 Mar;104(3):1563-1575. doi: 10.1007/s00277-025-06235-y. Epub 2025 Mar 10. PubMed 40063243 ↗

Study documents

  • Study protocol · Jun 5, 2023
  • Statistical analysis plan · Feb 22, 2024

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Sap, Csr

09

Registry details

Key details

Study ID
NCT03182244
Lead sponsor
Astellas Pharma Inc
Responsible party
Sponsor
First posted
Jun 9, 2017
Start date
Oct 25, 2017
Primary completion
Dec 25, 2023
Completion
Jul 29, 2026
Results posted
Jan 14, 2025
Last update
Sep 22, 2026

Study contacts

Medical Director
study director · Astellas Pharma Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion